Related Experiment Video

Updated: Jun 22, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid

H Miles Prince1, Mark J Bishton, Ricky W Johnstone

  • 1Peter MacCallum Cancer Centre Melbourne, Melbourne, Victoria, Australia. miles.prince@petermac.org

Future Oncology (London, England)
|June 13, 2009
PubMed

Insights

Panobinostat, a deacetylase inhibitor, shows preclinical and clinical promise in treating various cancers, including lymphomas and myeloid malignancies. Further research is ongoing for its application in hematologic and solid tumors.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Deacetylase inhibitors are a class of targeted antineoplastic agents.
  • These agents have shown preclinical activity in various malignancies.
  • Panobinostat is a widely studied deacetylase inhibitor.

Purpose of the Study:

  • To review preclinical data on panobinostat.
  • To discuss emerging clinical data from Phase I and II studies.
  • To highlight panobinostat's potential in treating hematologic and solid tumors.

Main Methods:

  • Review of preclinical studies on panobinostat.
  • Analysis of pharmacokinetic and pharmacodynamic data.
  • Examination of Phase I and II clinical trial results.

Main Results:

  • Panobinostat demonstrated significant preclinical activity across diverse malignancies.
  • Phase I and II studies showed favorable clinical activity in hematologic malignancies, particularly lymphomas and myeloid malignancies.
  • Extensive pharmacokinetic, pharmacodynamic, and dose-finding data are available.

Conclusions:

  • Panobinostat exhibits promising activity in preclinical and early clinical settings.
  • Its established data profile supports further investigation in cancer treatment.
  • Panobinostat represents a key deacetylase inhibitor in clinical development for various cancers.

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...